British journal of anaesthesia
-
Randomized Controlled Trial Comparative Study
Programmed intermittent bolus versus continuous infusion for catheter-based erector spinae plane block on quality of recovery in thoracoscopic surgery: a single-centre randomised controlled trial.
Regional anaesthesia techniques, including the erector spinae fascial plane (ESP) block, reduce postoperative pain after video-assisted thoracoscopic surgery (VATS). Fascial plane blocks rely on spread of local anaesthetic between muscle layers, and thus, intermittent boluses might increase their clinical effectiveness. We tested the hypothesis that postoperative ESP analgesia with a programmed intermittent bolus (PIB) regimen is better than a continuous infusion (CI) regimen in terms of quality of recovery after VATS. ⋯ Delivering ESP block analgesia after VATS via a PIB regimen resulted in similar QoR-15 at 24 h compared with a CI regimen.
-
Structured training in regional anaesthesia includes pretraining on simulation-based educational platforms to establish a safe and controlled learning environment before learners are provided clinical exposure in an apprenticeship model. This scoping review was designed to appraise the educational outcomes of current simulation-based educational modalities in regional anaesthesia. ⋯ There was significant heterogeneity in the types of simulation modalities used, teaching interventions applied, study methodologies, assessment tools, and outcome measures studied. When improvisations were made to regional anaesthesia simulation platforms (hybrid simulation), there were sustained educational improvements beyond 6 months. Newer technology-enhanced innovations such as virtual, augmented, and mixed reality simulations are evolving, with early reports of educational effectiveness.
-
Efficacy and safety of sugammadex for the reversal of neuromuscular blocking agents (NMBAs) in patients with neuromuscular diseases remains unclear. We summarised the available evidence and evaluated the quality of data reporting and the validity of published reports. ⋯ PROSPERO 2019 (CRD42019119924).